The global regenerative medicine market size value was US$ 10,107.32 million in 2020 and is estimated to reach US$ 83,196.72 million by 2030, growing at a CAGR of 23.4% during the forecast period from 2021 to 2030.
Regenerative medicine is a field of medicine that helps the body's damaged cells grow back and get fixed. These medications involve tissue engineering and stem cell therapies, which aid in the development of new, efficiently functioning organs. Because these cells are multipotent, these medications have the ability to generate a full organ. The cells are mostly extracted from umbilical cord blood and bone marrow.
Key Factors Contributing to the Global Market Growth
Effect of the COVID-19 Pandemic
According to a 2020 research article titled "Mesenchymal Stem Cell Therapy for COVID-19: Present or Future," published in the academic journal Aging and Disease, the rising COVID-19 cases worldwide has a profoundly positive impact on the market. Mesenchymal stem cells were a safe and effective approach to treating COVID-19. In May 2020, the Global Institute of Stem Cell Therapy and Research (GIOSTAR) approved the COVID-19 clinical trial employing stem cells to treat COVID-19. In addition, in May 2020, the United Arab Emirates Ministry of Economy received a patent for creating a unique and promising stem cell therapy for COVID-19 treatment. Thus, these expansions in stem cell research for COVID-19 have fueled the market growth.
Regional Overview
In 2020, North America held the largest regenerative medicine market share and will continue to hold this position during the forecast period. This is due to the significant capital investment, high patient disposable income, a large number of clinical studies, and supportive government policies for the commercialization of tissue engineering and regenerative medicine products. In addition, an increase in the number of regenerative medicine product approvals, the presence of key players, and advancements in technology for healthcare in the region drive market growth in the region.
In the upcoming years, Asia Pacific is likely to experience the fastest growth rate. The increasing acceptance of cell-based methods in healthcare, the rise in the number of elderly people in the area, and the development of important companies are all cited as reasons for this expansion. China has recently emerged with rapid infrastructure and facility expansion to strengthen stem cell research. As a result, this factor will boost the market growth.
Prominent Companies
Some of the well-known companies profiled in the global regenerative medicine market are:
Segmentation Outline
The global regenerative medicine market segmentation focuses on Product Type, Material, Application, and Region.
Segmentation based on Product Type
Segmentation based on Material
Segmentation based on Application
Segmentation based on Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL REGENERATIVE MEDICINE MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
4 GLOBAL REGENERATIVE MEDICINE MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE MODEL
4.4 VALUE CHAIN ANALYSIS
5 GLOBAL REGENERATIVE MEDICINE MARKET, BY PRODUCT TYPE
5.1 OVERVIEW
5.2 CELL THERAPY
5.3 GENE THERAPY
5.4 TISSUE ENGINEERING
5.5 SMALL MOLECULE & BIOLOGIC
6 GLOBAL REGENERATIVE MEDICINE MARKET, BY MATERIAL
6.1 OVERVIEW
6.2 SYNTHETIC MATERIAL
6.2.1 SCAFFOLD
6.2.2 ARTIFICIAL VASCULAR GRAFT MATERIAL
6.2.3 HYDROGEL MATERIAL
6.3 BIOLOGICALLY DERIVED MATERIAL
6.3.1 COLLAGEN
6.3.2 XENOGENEIC MATERIAL
6.4 GENETICALLY ENGINEERED MATERIAL
6.4.1 GENETICALLY MANIPULATED CELL
6.4.2 THREE-DIMENSIONAL POLYMER TECHNOLOGY
6.4.3 TRANSGENICS
6.4.4 FIBROBLAST
6.4.5 NEURAL STEM CELL
6.4.6 GENE-ACTIVATED MATRICES
6.5 PHARMACEUTICAL
6.5.1 BIOLOGIC
7 GLOBAL REGENERATIVE MEDICINE MARKET, BY APPLICATION
7.1 OVERVIEW
7.2 CARDIOVASCULAR
7.3 ONCOLOGY
7.4 DERMATOLOGY
7.5 MUSCULOSKELETAL
7.6 WOUND HEALING
7.7 OPHTHALMOLOGY
7.8 NEUROLOGY
7.9 OTHERS
8 GLOBAL REGENERATIVE MEDICINE MARKET, BY GEOGRAPHY
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 NORTH AMERICA MARKET SNAPSHOT
8.2.2 U.S.
8.2.3 CANADA
8.2.4 MEXICO
8.3 EUROPE
8.3.1 EUROPE MARKET SNAPSHOT
8.3.2 WESTERN EUROPE
8.3.2.1 THE UK
8.3.2.2 GERMANY
8.3.2.3 FRANCE
8.3.2.4 ITALY
8.3.2.5 SPAIN
8.3.2.6 REST OF WESTERN EUROPE
8.3.3 EASTERN EUROPE
8.3.3. 1 POLAND
8.3.3.2 RUSSIA
8.3.3.3 REST OF EASTERN EUROPE
8.4 ASIA PACIFIC
8.4.1 ASIA PACIFIC MARKET SNAPSHOT
8.4.2 CHINA
8.4.3 JAPAN
8.4.4 INDIA
8.4.5 AUSTRALIA & NEW ZEALAND
8.4.6 ASEAN
8.4.7 REST OF ASIA PACIFIC
8.5 MIDDLE EAST & AFRICA
8.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
8.5.2 UAE
8.5.3 SAUDI ARABIA
8.5.4 SOUTH AFRICA
8.5.5 REST OF MEA
8.6 SOUTH AMERICA
8.6.1 SOUTH AMERICA MARKET SNAPSHOT
8.6.2 BRAZIL
8.6.3 ARGENTINA
8.6.4 REST OF SOUTH AMERICA
9 GLOBAL REGENERATIVE MEDICINE MARKET COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPANY MARKET RANKING
9.3 KEY DEVELOPMENT STRATEGIES
10 COMPANY PROFILES
10.1 3M COMPANY
10.1.1 OVERVIEW
10.1.2 FINANCIAL PERFORMANCE
10.1.3 PRODUCT OUTLOOK
10.1.4 KEY DEVELOPMENTS
10.2 ATHERSYS, INC.
10.2.1 OVERVIEW
10.2.2 FINANCIAL PERFORMANCE
10.2.3 PRODUCT OUTLOOK
10.2.4 KEY DEVELOPMENTS
10.3 CRYOLIFE, INC.
10.3.1 OVERVIEW
10.3.2 FINANCIAL PERFORMANCE
10.3.3 PRODUCT OUTLOOK
10.3.4 KEY DEVELOPMENTS
10.4 INTEGRA LIFESCIENCES CORPORATION
10.4.1 OVERVIEW
10.4.2 FINANCIAL PERFORMANCE
10.4.3 PRODUCT OUTLOOK
10.4.4 KEY DEVELOPMENTS
10.5 ISTO BIOLOGICS (ISTO BIOLOGICS MEDICAL SYSTEMS, INC.)
10.5.1 OVERVIEW
10.5.2 FINANCIAL PERFORMANCE
10.5.3 PRODUCT OUTLOOK
10.5.4 KEY DEVELOPMENTS
10.6 MEDTRONIC PLC
10.6.1 OVERVIEW
10.6.2 FINANCIAL PERFORMANCE
10.6.3 PRODUCT OUTLOOK
10.6.4 KEY DEVELOPMENTS
10.7 ORGANOGENESIS INC.
10.7.1 OVERVIEW
10.7.2 FINANCIAL PERFORMANCE
10.7.3 PRODUCT OUTLOOK
10.7.4 KEY DEVELOPMENTS
10.8 STRYKER CORPORATION
10.8.1 OVERVIEW
10.8.2 FINANCIAL PERFORMANCE
10.8.3 PRODUCT OUTLOOK
10.8.4 KEY DEVELOPMENTS
10.9 U.S. STEM CELL, INC.
10.9.1 OVERVIEW
10.9.2 FINANCIAL PERFORMANCE
10.9.3 PRODUCT OUTLOOK
10.9.4 KEY DEVELOPMENTS
10.10 ZIMMER BIOMET HOLDINGS, INC.
10.10.1 OVERVIEW
10.10.2 FINANCIAL PERFORMANCE
10.10.3 PRODUCT OUTLOOK
10.10.4 KEY DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved